Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
BioRx

BioRx Introduces National Physical Therapy Program

CINCINNATI, Ohio  - BioRx announced today the launch of a new physical therapy program to help patients, physicians, physical therapists, and health insurers manage the complications and costs of hemophilia-related joint damage. The program, called REBUILD, supports a patient’s physical therapy program at the local level. Under the direction of an experienced physical therapist for […]

NY Times: Dispute Develops Over Discount Drug Program

By: Andrew Pollack  When a private oncology practice in Memphis formed a partnership with a nearby hospital in late 2011, the organizations proclaimed that the deal would “transform cancer care” in the region. What they did not emphasize was that the deal would also create a windfall for them worth millions of dollars a year, […]

ATHN and The Hemophilia Alliance Announce Memorandum of Understanding

February 6, 2013  – The Hemophilia Alliance and the American Thrombosis and Hemostasis Network (ATHN) are pleased to announce they have entered into a Memorandum of Understanding to provide financial assistance to ATHN in support of the ATHN Data Quality Counts program for Hemophilia Treatment Centers (HTCs) across the country. Funding from the Hemophilia Alliance […]

PSI and Bayer Healthcare Introduce Co-Pay/Co-Insurance Pilot Program

Midlothian, VA and Wayne, NJ –January 24, 2013 – Patient Services, Inc. (PSI) and Bayer HealthCare are pleased to announce the Kogenate® FS Co-pay/Co-Insurance Assistance Pilot Program. The pilot program is funded by Bayer to help qualified Kogenate® FS patients with their out-of-pocket payments. What is offered through the pilot program? PSI will administer and […]

Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy For Hemophilia B

WESTON, Mass.– Today, Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. rFIXFc is the first product candidate in a new class of long-lasting clotting factor therapies that […]

Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek Combination Treatment): Drug Safety Communication – Serious Skin Reactions

AUDIENCE: Internal Medicine, Gastroenterology, Dermatology ISSUE: FDA received reports of serious skin reactions, some fatal, in patients taking the hepatitis C drug Incivek (telaprevir) in combination with the drugs peginterferon alfa and ribavirin (Incivek combination treatment). Some patients died when they continued to receive Incivek combination treatment after developing a worsening, or progressive rash and […]

Pfizer Hemophilia: The Way You Log Is About To Change

Pfizer Hemophilia is excited to announce the launch of its first mobile logging tool, HemMobile™, a free mobile app designed to help hemophilia patients and caregivers using any factor replacement product log infusions and bleeds and stay aware of general health and wellness. Developed with input from members of the bleeding disorders community, HemMobile™ was […]

Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events

Princeton, N.J. (November 27, 2012) — Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events. The app offers multiple profiles so that more than one family […]

Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A in the US and EU

Novo Nordisk today announced the submission of the regulatory application for turoctocog alfa (NN7008) to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Turoctocog alfa is a third-generation recombinant coagulation factor VIII intended for prevention and treatment of bleeding in people with haemophilia A. “We are very excited about having […]

Biogen's Hemophilia Drug Meets Late-stage Trial Goal

(Reuters) – Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia B, a rare inherited blood disorder that impairs coagulation, met the main goal of controlling bleeding in a late-stage trial. A single injection of the long-lasting clotting factor, being developed in partnership with Swedish Orphan Biovitrum, controlled bleeding in 90.4 […]

Page 5 of 1312345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community